

**Supplementary Table 5. Difference in sensitivity and specificity between imaging tools for detecting hepatic steatosis ≥5%**

	Difference in sensitivity				Difference in specificity			
	MRI-PDFF	CAP	Grayscale US	ATI	MRI-PDFF	CAP	Grayscale US	ATI
CT	19.7* [7.7 to 31.7]	-9.1 [-23.5 to 5.3]	-1.5 [-13.8 to 10.7]	9.1 [-3.3 to 21.5]	11.1 [1.3 to 20.9]	7.4 [-5.0 to 19.8]	-5.6 [-19.5 to 8.4]	11.1 [0.1 to 22.2]
MRI-PDFF		-28.8* [-39.7 to -17.9]	-21.2* [-31.9 to -10.5]	-10.6 [-21.8 to 0.6]		-3.7 [-10.9 to 3.5]	-16.7* [-27.9 to -5.5]	0 [-7.3 to 7.3]
CAP			7.6 [-4.5 to 19.7]	18.2* [5.0 to 31.4]			-13.0 [-25.6 to -0.3]	3.7 [-3.5 to 10.9]
Grayscale US				10.8 [-1.4 to 22.6]				16.7* [5.5 to 27.9]

Values obtained by subtracting the value of the y-axis item from the value of the x-axis item, with 95% confidence intervals in brackets.

MRI-PDFF, magnetic resonance imaging-derived proton density fat fraction; CAP, controlled attenuation parameter; US, ultrasound; ATI, attenuation imaging; CT, computed tomography.

\*P<0.05.

**Supplementary Table 6. Difference in sensitivity and specificity between imaging tools for detecting hepatic steatosis >33%**

	Difference in sensitivity				Difference in specificity			
	MRI-PDFF	CAP	Grayscale US	ATI	MRI-PDFF	CAP	Grayscale US	ATI
CT	Not estimable	12.5 [-3.7 to 28.7]	-25.0 [-46.2 to -3.8]	12.5 [-3.7 to 28.7]	10.6* [4.7 to 16.5]	-13.5* [-23.1 to -3.8]	8.7* [2.1 to 15.2]	-14.4* [-22.2 to -6.7]
MRI-PDFF		12.5 [-3.7 to 28.7]	-25.0 [-46.2 to -3.8]	12.5 [-3.7 to 28.7]		-24.0* [-32.3 to -15.8]	-1.9 [-5.7 to 1.8]	-25.0* [-33.3 to -16.7]
CAP			-37.5* [-61.2 to -13.8]	Not estimable			22.1* [13.7 to 30.5]	-1.0 [-10.8 to 8.8]
Grayscale US				37.5* [13.8 to 61.2]				-23.1* [-31.6 to -14.6]

Values obtained by subtracting the value of the y-axis item from the value of the x-axis item, with 95% confidence intervals in brackets.

MRI-PDFF, magnetic resonance imaging-derived proton density fat fraction; CAP, controlled attenuation parameter; US, ultrasound; ATI, attenuation imaging; CT, computed tomography.

\*P<0.05.

**Supplementary Table 7. Difference in sensitivity and specificity between imaging tools for detecting hepatic steatosis ≥10%**

	Difference in sensitivity				Difference in specificity			
	MRI-PDFF	CAP	Grayscale US	ATI	MRI-PDFF	CAP	Grayscale US	ATI
CT	25.0* [12.2 to 37.8]	6.8 [-9.1 to 22.8]	9.1 [-6.1 to 24.3]	11.4 [-1.6 to 24.3]	0 [-8.9 to 8.9]	0 [-10.9 to 10.9]	-14.5* [-25.8 to -3.1]	-1.3 [-10.6 to 8.0]
MRI-PDFF		-18.2* [-29.6 to -6.8]	-15.9* [-26.7 to -5.1]	-13.6* [-23.8 to -3.5]		0 [-8.9 to 8.9]	-14.5* [-24.6 to -4.4]	-1.3 [-9.9 to 7.2]
CAP			2.3 [-9.5 to 14.0]	4.6* [-9.5 to 18.6]			-14.5* [-26.4 to -2.5]	-1.3 [-11.9 to 9.3]
Grayscale US				2.3 [-11.1 to 15.6]				13.2 [0.9 to 25.4]

Values obtained by subtracting the value of the y-axis item from the value of the x-axis item, with 95% confidence intervals in brackets.

MRI-PDFF, magnetic resonance imaging-derived proton density fat fraction; CAP, controlled attenuation parameter; US, ultrasound; ATI, attenuation imaging; CT, computed tomography.

\*P<0.05.